Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Immune checkpoint inhibitors have revolutionized the treatment of multiple solid malignancies, but their role in the treatment of neuroendocrine neoplasms (NEN) is unclear. The accompanying article reports on a study combining the programmed cell death (PD-1) inhibitor nivolumab with the alkylating agent temozolomide in patients with advanced NENs. See related article by Owen et al., p. 731.

Keyphrases

emergency department
newly diagnosed
adverse drug